Arca
Skip to content
Tools
Tools

TOP1: DNA topoisomerase 1

Releases the supercoiling and torsional tension of DNA introduced during the DNA replication and transcription by transiently cleaving and rejoining one strand of the DNA duplex.

  • Drugs that act on it: 24
  • Approved: 4
  • In phases 1 to 3: 20
  • Sponsors: 18

Who is on it, and how far along

Every drug ChEMBL records acting on TOP1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 16
  • Antibody-drug conjugate 5
  • Other 3

Approved4

  • Irinotecan
  • Trastuzumab deruxtecan
  • Sacituzumab govitecan
  • Topotecan

Phase 310

  • Irinotecan sucrosofate
  • Datopotamab deruxtecan
  • Patritumab deruxtecan
  • Exatecan
  • Becatecarin
  • Belotecan
  • Edotecarin
  • Etirinotecan pegol
  • Karenitecin
  • Rubitecan

Phase 210

  • 7-ETHYL-10-HYDROXYCAMPTOTHECIN
  • 9-AMINOCAMPTOTHECIN
  • Afeletecan
  • AR-67
  • CAMPTOTHECIN-20-O-PROPIONATE
  • Diflomotecan
  • Gimatecan
  • Labetuzumab govitecan
  • Mureletecan
  • TLC-388

Phase 10

    Sponsors

    Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

    • Arno Therapeutics14%
    • Astex Pharmaceuticals, Inc.14%
    • BioNumerik Pharmaceuticals, Inc.14%
    • Chengdu SciMount Pharmatech Co., Ltd.14%
    • Chong Kun Dang Pharmaceutical14%
    • Genfleet Therapeutics (Shanghai) Inc.14%

    The landscape

    Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. 22 of 24 act as: DNA topoisomerase I inhibitor; the rest name their own mechanism.
    IrinotecanBoxed warningApprovedPfizerSmall moleculeInhibitor619
    Trastuzumab deruxtecanBoxed warningApprovedChengdu SciMount Pharmatech Co., Ltd.Antibody-drug conjugateInhibitor186
    Sacituzumab govitecanBoxed warningApprovedGilead SciencesAntibody-drug conjugateInhibitor137
    TopotecanBoxed warningApprovedSandozSmall moleculeInhibitor100
    Irinotecan sucrosofatePhase 3MediLink Therapeutics (Suzhou) Co., Ltd.OtherInhibitor82
    Datopotamab deruxtecanPhase 3Daiichi SankyoAntibody-drug conjugateInhibitor48
    Patritumab deruxtecanPhase 3Merck & Co. (MSD)Antibody-drug conjugateInhibitor22
    ExatecanPhase 3Merck KGaASmall moleculeInhibitor15
    BecatecarinPhase 3Helsinn HealthcareSmall moleculeInhibitor0
    BelotecanPhase 3Chong Kun Dang PharmaceuticalSmall moleculeInhibitor0
    EdotecarinPhase 3PfizerSmall moleculeInhibitor0
    Etirinotecan pegolPhase 3Nektar TherapeuticsOtherInhibitor0
    KarenitecinPhase 3BioNumerik Pharmaceuticals, Inc.Small moleculeInhibitor0
    RubitecanPhase 3Astex Pharmaceuticals, Inc.Small moleculeInhibitor0
    7-ETHYL-10-HYDROXYCAMPTOTHECINPhase 2Genfleet Therapeutics (Shanghai) Inc.Small moleculeInhibitor619
    9-AMINOCAMPTOTHECINPhase 2—Small moleculeInhibitor0
    AfeletecanPhase 2—Small moleculeStabiliserDNA topoisomerase I stabiliser0
    AR-67Phase 2Arno TherapeuticsSmall moleculeInhibitor0
    CAMPTOTHECIN-20-O-PROPIONATEPhase 2—Small moleculeInhibitor0
    DiflomotecanPhase 2IpsenSmall moleculeInhibitor0
    GimatecanPhase 2Lee's PharmSmall moleculeInhibitor0
    Labetuzumab govitecanPhase 2—Antibody-drug conjugateInhibitorDNA topoisomerase 1 inhibitor0
    MureletecanPhase 2—OtherInhibitor0
    TLC-388Phase 2Taiwan Liposome CompanySmall moleculeInhibitor0

    Open trials

    The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 61 in all, from ClinicalTrials.gov.
    A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCDatopotamab deruxtecanPhase 2Not yet recruitingAstraZenecaNov 17, 2026
    A Phase 2 Study of Bevacizumab Plus Erlotinib in EGFR-Amplified Metastatic Colorectal CancerIrinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECINPhase 2Not yet recruitingKorea University Anam HospitalNov 17, 2026
    A Trial Evaluating the Anti-tumor Activity of Antibody-based Therapies in Metastatic Cancer PatientsTrastuzumab deruxtecanPhase 2Not yet recruitingCentre Leon BerardNov 13, 2026
    Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaIrinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECINPhase 2RecruitingGiselle ShollerNov 12, 2026
    Phase 1b/2 to Evaluate the Safety, Tolerability, and Efficacy of TXN10128 in Combination With TOPO-I Inhibitor-based Therapies (Irinotecan or TROP2 ADC) in Advanced or Metastatic EGFR Mutated NSCLCIrinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECINPhase 1 / Phase 2RecruitingTxinno Bioscience Inc.Nov 12, 2026
    A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With ObrixtamigTopotecanPhase 3Not yet recruitingBoehringer IngelheimNov 10, 2026
    A Study of QLS5132 in Platinum-Resistant Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTopotecanPhase 3Not yet recruitingQilu Pharmaceutical Co., Ltd.Nov 9, 2026
    A Phase Ib/II Study of GFH276 in Combination With Chemotherapy (± Bevacizumab) or Cetuximab in Patients With RAS-mutant Metastatic Colorectal CancerIrinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECINPhase 1 / Phase 2Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.Nov 4, 2026
    A Study of QLS5314 Monotherapy in Participants With Advanced Solid TumorsExatecanPhase 1Not yet recruitingShanghai Qilu Pharmaceutical Research and Development Center LTDNov 4, 2026
    A Study of SYH2051 in Combination With Irinotecan Hydrochloride Liposome Injection in Subjects With Advanced Solid TumorsIrinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECINPhase 1 / Phase 2Not yet recruitingCSPC ZhongQi Pharmaceutical Technology Co., Ltd.Nov 3, 2026
    GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal CancerIrinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECINPhase 3Not yet recruitingGenfleet Therapeutics (Shanghai) Inc.Nov 3, 2026
    A Study of Perioperative Navlimetostat Combined With Modified FOLFIRINOX in Patients With MTAP-Deleted Pancreatic CancerIrinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECINPhase 1 / Phase 2Not yet recruitingDaniel Nussbaum, M.D.Oct 29, 2026
    Study of Trastuzumab Deruxtecan in Combination With Stereotactic Radiosurgery in Patients With HER2-Positive Metastatic Breast Cancer and First Diagnosis of Brain Metastases (HERBRAIN)Trastuzumab deruxtecanPhase 2Not yet recruitingAzienda Ospedaliero-Universitaria CareggiOct 29, 2026
    Toripalimab Plus Cetuximab and Irinotecan for Second-Line Right-Sided RAS/BRAF Wild-Type Advanced Colon Cancer Phase II StudyIrinotecan, 7-ETHYL-10-HYDROXYCAMPTOTHECINPhase 2RecruitingCancer Institute and Hospital, Chinese Academy of Medical SciencesOct 27, 2026
    Trastuzumab Rezetecan Followed by Pyrotinib, Fulvestrant, and Dalpiciclib in HR-Positive, HER2-Positive Advanced Breast CancerExatecanPhase 3Not yet recruitingSun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOct 23, 2026
    A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]Datopotamab deruxtecanPhase 1 / Phase 2RecruitingDaiichi SankyoOct 22, 2026
    Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene AbnormalitiesTopotecanPhase 1RecruitingBeijing Tongren HospitalOct 22, 2026
    TROPION Breast Respond in 1L TNBCDatopotamab deruxtecan—Not yet recruitingDaiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyOct 9, 2026
    Phase 1/2 Multicenter, Open-label, Dose-escalation Study of IDP- 121 in Patients With Platinum-resistant Small Cell Lung Cancer (MYCrocytic)TopotecanPhase 1 / Phase 2RecruitingIDP Discovery Pharma S.L.Oct 7, 2026
    Zanidatamab Combined With Liposomal Irinotecan and Capecitabine for Second-line Treatment of HER2-positive Unresectable Biliary Tract TumorsIrinotecan sucrosofatePhase 2Not yet recruitingAnhui Provincial HospitalSep 25, 2026
    A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXdTrastuzumab deruxtecanPhase 2Not yet recruitingFujian Medical UniversitySep 23, 2026
    A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to TreatExatecanPhase 1 / Phase 2Not yet recruitingChildren's Oncology GroupSep 21, 2026
    Premedication With Dexamethasone for Preventing Interstitial Lung Disease in Patients With Breast Cancer Treated With Trastuzumab DeruxtecanTrastuzumab deruxtecanPhase 3Not yet recruitingMario Negri Institute for Pharmacological ResearchSep 18, 2026
    Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast CancerDatopotamab deruxtecan, Sacituzumab govitecan, Trastuzumab deruxtecanPhase 2Not yet recruitingFudan UniversitySep 17, 2026
    Sacituzumab Govitecan Combined With Tislelizumab for Locally Advanced/Metastatic Esophageal CancerSacituzumab govitecanPhase 2RecruitingShanghai Chest HospitalSep 10, 2026
    A Study to Compare the Efficacy and Safety of YL201 With Standard Chemotherapy in Patients With Metastatic Pancreatic Cancer After Failure of Gemcitabine-Based Systemic ChemotherapyIrinotecan sucrosofatePhase 3Not yet recruitingMediLink Therapeutics (Suzhou) Co., Ltd.Sep 4, 2026
    JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical CancerTopotecanPhase 3Not yet recruitingJiangsu Alphamab Biopharmaceuticals Co., LtdSep 1, 2026
    Sacituzumab Govitecan and Q901 in Advanced TNBCSacituzumab govitecanPhase 2Not yet recruitingYonsei UniversityAug 26, 2026
    Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast CancerTrastuzumab deruxtecanPhase 1 / Phase 2Not yet recruitingThe Methodist Hospital Research InstituteAug 25, 2026
    Liposomal Irinotecan Plus Cisplatin in Patients With Advanced or Metastatic Solid MalignanciesIrinotecan sucrosofatePhase 1Not yet recruitingNational Health Research Institutes, TaiwanAug 24, 2026
    A Study of T-DXd in AI-Assessed HER2-Ultralow Metastatic Breast CancerTrastuzumab deruxtecanNot applicableNot yet recruitingShuangyue LiuAug 24, 2026
    A Multicenter, Prospective, Phase II Study of TROP-2 ADC in Combination With Toripalimab for Resectable Locally Advanced Oral Squamous Cell CarcinomaSacituzumab govitecanPhase 2Not yet recruitingShanghai East HospitalAug 21, 2026
    A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid TumorsExatecanPhase 1 / Phase 2RecruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Aug 4, 2026
    GB268 Monotherapy or Combination Therapy for Locally Advanced/Metastatic Breast Cancer (Phase Ib/Ⅱ)Datopotamab deruxtecanPhase 1 / Phase 2Not yet recruitingEddingpharm (Zhuhai) Co., Ltd.Jul 31, 2026
    SMP-656 for HER2-Positive Advanced Breast CancerTrastuzumab deruxtecanPhase 2RecruitingChengdu SciMount Pharmatech Co., Ltd.Jul 24, 2026
    An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCDatopotamab deruxtecanPhase 3RecruitingAstraZenecaJul 22, 2026
    A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube CancersTopotecanPhase 3RecruitingCSPC Megalith Biopharmaceutical Co.,Ltd.Jul 16, 2026
    A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast CancerPatritumab deruxtecanPhase 1 / Phase 2RecruitingDaiichi SankyoJul 14, 2026
    A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal CancerExatecanPhase 1 / Phase 2RecruitingSOTIO Biotech a.s.Jul 9, 2026
    IMMU-132 in TROP-2 Overexpressed Advanced and Relapsed Ovarian CancerSacituzumab govitecanPhase 1Not yet recruitingShanghai Gynecologic Oncology GroupJun 29, 2026
    Optimal Application Timing of ADC Drugs for Advanced Breast CancerSacituzumab govitecanPhase 2RecruitingLiaoning Cancer Hospital & InstituteJun 18, 2026
    Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic CholangiocarcinomaIrinotecan sucrosofatePhase 2Active, not recruitingTianjin Medical University Cancer Institute and HospitalJun 15, 2026
    Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer OrganoidsSacituzumab govitecan—RecruitingGuangzhou Institute of Respiratory DiseaseMay 28, 2026
    An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in ChinaTopotecanPhase 3RecruitingGenmabMay 22, 2026
    Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian CancerIrinotecan sucrosofatePhase 2Not yet recruitingTianjin Medical University Cancer Institute and HospitalMay 18, 2026
    Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic ResponseDatopotamab deruxtecan, Sacituzumab govitecan—RecruitingFundación Pública Andaluza para la Investigación Biomédica Andalucía OrientalMay 13, 2026
    A Clinical Study of Liposomal Irinotecan for Second-Line Therapy in Metastatic Colorectal CancerIrinotecan sucrosofatePhase 2 / Phase 3Not yet recruitingHebei Medical University Fourth HospitalMay 13, 2026
    Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver MetastasesIrinotecan sucrosofatePhase 2Not yet recruitingTianjin Medical University Cancer Institute and HospitalMay 6, 2026
    A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)ExatecanPhase 3RecruitingEMD Serono Research & Development Institute, Inc.Apr 24, 2026
    A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein ExpressionTopotecanPhase 3RecruitingK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncApr 22, 2026
    Liposomal Irinotecan, 5-fluorouracil/Calcium Folinate, Oxaliplatin, and Adebrelimab in Combination With Radiotherapy for Resectable or Borderline Resectable Pancreatic Cancer With Risk Factors:A Prospective Exploratory StudyIrinotecan sucrosofatePhase 2RecruitingNingbo Medical Center Lihuili HospitalApr 21, 2026
    SCALp Cooling for pReventing aLopecia With nEw anTibody-drug ConjugatesDatopotamab deruxtecanPhase 2RecruitingJules Bordet InstituteMar 16, 2026
    AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsExatecanPhase 1RecruitingAvacta Life Sciences LtdMar 6, 2026
    Anti-Ly6E Exatecan ADC M7437 in Advanced Solid TumorsExatecanPhase 1RecruitingEMD Serono Research & Development Institute, Inc.Jan 22, 2026
    A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)Patritumab deruxtecanPhase 1 / Phase 2RecruitingMerck Sharp & Dohme LLCDec 16, 2025
    A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)Patritumab deruxtecanPhase 3RecruitingMerck Sharp & Dohme LLCJul 11, 2025
    A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)Patritumab deruxtecanPhase 1 / Phase 2RecruitingMerck Sharp & Dohme LLCApr 23, 2025
    Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)Patritumab deruxtecanPhase 2RecruitingMerck Sharp & Dohme LLCJan 28, 2025
    A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)Patritumab deruxtecanPhase 2RecruitingMerck Sharp & Dohme LLCDec 13, 2024
    Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)Patritumab deruxtecanPhase 1 / Phase 2RecruitingMerck Sharp & Dohme LLCNov 13, 2024
    Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02)Patritumab deruxtecanPhase 1 / Phase 2Active, not recruitingMerck Sharp & Dohme LLCSep 19, 2024

    Diseases most associated with it

    Open Targets association score, 0 to 1; all associations
    Small cell lung carcinoma
    0.65
    Neoplasm
    0.61
    Non-small cell lung carcinoma
    0.58
    Triple-negative breast carcinoma
    0.54
    Pancreatic neoplasm
    0.53
    Neurodegenerative disease
    0.52
    Breast neoplasm
    0.51

    Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1781, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P11387, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

    Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.